Study highlights limitations of IP drug delivery

An Australian study has highlighted the limitations of intraperitoneal (IP) drug delivery in ovarian cancer, with the majority of patients demonstrating multiple regions of faint or absent uptake on scintigraphic peritoneography imaging. Writing in the Internal Medicine Journal, oncologists from the Peter MacCallum Cancer Centre, Mercy Hospital, Monash Medical Centre and the Royal Women’s Hospital in Melbourne explained that recent trials had supported the use of IP chemotherapy for women with optimally debulked epithelial ovarian cancer. “Although the subject of IP chemotherapy in ovarian cancer continues to engender considerable controversy many clinicians have responded to these recent results…by offering IP chemotherapy to this patient population,” they wrote....